These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 3724862)

  • 41. [Dangers in drug therapy of Parkinson's disease].
    Gehlen W
    Z Allgemeinmed; 1975 Nov; 51(33):1543-4. PubMed ID: 1210361
    [No Abstract]   [Full Text] [Related]  

  • 42. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 43. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The management approaches to dyskinesia vary from country to country.
    Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
    Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Baron MS; Dalton WB
    Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933
    [No Abstract]   [Full Text] [Related]  

  • 46. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term electrostimulation of the ventroposterolateral pallidum in the treatment of Parkinson's disease.
    Siegfried J; Taub E; Wellis GN
    Adv Neurol; 1999; 80():623-6. PubMed ID: 10410780
    [No Abstract]   [Full Text] [Related]  

  • 49. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 50. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher-dose glutathione therapy for Parkinson's disease in Japan: is it really safe?
    Naito Y; Matsuo K; Kokubo Y; Narita Y; Tomimoto H
    Mov Disord; 2010 May; 25(7):962; author reply 962-3. PubMed ID: 20131395
    [No Abstract]   [Full Text] [Related]  

  • 52. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Bode M
    Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 54. [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
    Nakamura Y; Yoshinaga J; Endo S; Hikiji A
    Rinsho Shinkeigaku; 1997 Jun; 37(6):469-75. PubMed ID: 9366172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 56. Drugs for Parkinson's Disease.
    Treat Guidel Med Lett; 2004 Jun; 2(22):41-6. PubMed ID: 15529113
    [No Abstract]   [Full Text] [Related]  

  • 57. Effective strategies in the management of Parkinson's disease.
    Wills AJ
    Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Parkinson's disease in the elderly: therapeutic note].
    Mantovani M; Bonati PA; Pioli G; Ciotti G; Pedrazzoni M
    G Clin Med; 1987 May; 68(5):303-7. PubMed ID: 3622996
    [No Abstract]   [Full Text] [Related]  

  • 59. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
    Jansen EN; van Laar T
    Ned Tijdschr Geneeskd; 1990 May; 134(18):889-91. PubMed ID: 2345577
    [No Abstract]   [Full Text] [Related]  

  • 60. Current and emerging drug therapies in the management of Parkinson's disease.
    Koller WC; Tolosa E
    Neurology; 1998 Jun; 50(6 Suppl 6):S1. PubMed ID: 9633678
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.